Table 1

Studies included in the pooled analysis of GSTM1 and GSTT1 genotype

Study(label)CasesControlsDefinition of the control populationMen %Age means ± SDSmokers %PckY means ± SDAsbestos (% E+)a
Case control studies
 London et al., 1995—Caucasian (US Cauc)b145380Healthy controls from the general population5562.9 ± 9.37130.6 ± 34.917.5
 London et al., 1995—African-American (US-AA)c121192Stratified on age (±10 years), sex, and ethnicity5562.8 ± 8.37927.7 ± 30.323.0
 Stücker et al, 1999 (France 1)d239242Hospital-based controls10059.4 ± 9.89031.9 ± 23.17.1
Matched on age (±2.5 years), sex, and hospital
Excluding patient with lung disease or previous cancer
 Jourenkova et al, 1997 (France 2)e146169Hospital-based controls9556.4 ± 10.610043.7 ± 26.512.4
Matched on age (±3 years), sex, and hospital
Excluding patients with prior or current malignant disease
Case-only series
 Anttila, Hirvonen et al., 1995 (Finland)f2187861.6 ± 9.79335.5 ± 23.935.3
  • a Prevalence of exposure on the whole population.

  • b Subjects (132) of the initial study are missing: 13 subjects were missing in the GSEC database, 123 were excluded since they have been exposed to both asbestos and PAH (cf p 6), and 1 for GSTM1 missing.

  • c Subjects (112) of the initial study are missing: 20 subjects were missing in the GSEC database; 92 were excluded since they have been exposed to both asbestos and PAH (cf p. 6).

  • d Subjects (131) of the initial study are missing: 111 with GSTM1 missing and 20 with pack-years missing.

  • e Subjects (7) of the initial study are missing, all because of pack-years.

  • f Subjects (9) of the initial study are missing.